Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Bell Gorrod

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 6, 2019
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case StudyAsh Bullement, Nicholas R Latimer, Helen Bell Gorrod
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2020
Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South AfricaHelen Bell Gorrod, Richard Court, Michael Schomaker, et al.
Health Policy OPEN|December 26, 2025
The NICE experience of designing and utilising severity weightsAllan Wailoo, Helen Bell Gorrod, Lorna Dunning, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2019
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension StudyHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Advances in Therapy|November 9, 2019
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment MethodsHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
BJU International|April 19, 2025
Long-term cost-effectiveness of invasive urodynamic studies for overactive bladder in womenHelen Bell-Gorrod, Praveen Thokala, Suzanne Breeman, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 12, 2019
A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for ImprovementHelen Bell Gorrod, Ben Kearns, John Stevens, et al.
American Journal of Epidemiology|March 29, 2020
The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at FailureHelen Bell-Gorrod, Matthew P Fox, Andrew Boulle, et al.
Statistical Methods in Medical Research|January 17, 2025
Adjusting for switches to multiple treatments: Should switches be handled separately or combined?Helen Bell Gorrod, Shahrul Mt-Isa, Jingyi Xuan, et al.
Statistical Methods in Medical Research|December 13, 2024
Is inverse probability of censoring weighting a safer choice than per-protocol analysis in clinical trials?Jingyi Xuan, Shahrul Mt-Isa, Nicholas Latimer, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 6, 2019
Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case StudyAsh Bullement, Nicholas R Latimer, Helen Bell Gorrod
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2020
Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South AfricaHelen Bell Gorrod, Richard Court, Michael Schomaker, et al.
Health Policy OPEN|December 26, 2025
The NICE experience of designing and utilising severity weightsAllan Wailoo, Helen Bell Gorrod, Lorna Dunning, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 7, 2019
Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension StudyHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
Advances in Therapy|November 9, 2019
Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment MethodsHelen Bell Gorrod, Nicholas R Latimer, Doris Damian, et al.
BJU International|April 19, 2025
Long-term cost-effectiveness of invasive urodynamic studies for overactive bladder in womenHelen Bell-Gorrod, Praveen Thokala, Suzanne Breeman, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|November 12, 2019
A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for ImprovementHelen Bell Gorrod, Ben Kearns, John Stevens, et al.
American Journal of Epidemiology|March 29, 2020
The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at FailureHelen Bell-Gorrod, Matthew P Fox, Andrew Boulle, et al.
Statistical Methods in Medical Research|January 17, 2025
Adjusting for switches to multiple treatments: Should switches be handled separately or combined?Helen Bell Gorrod, Shahrul Mt-Isa, Jingyi Xuan, et al.
Statistical Methods in Medical Research|December 13, 2024
Is inverse probability of censoring weighting a safer choice than per-protocol analysis in clinical trials?Jingyi Xuan, Shahrul Mt-Isa, Nicholas Latimer, et al.
Pageof 2